NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

骨關節炎(OA):現在的市場機會與今後預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析

Osteoarthritis (OA) - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024245
出版日期 內容資訊 英文 287 Pages
商品交期: 3-5個工作天內
價格
骨關節炎(OA):現在的市場機會與今後預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析 Osteoarthritis (OA) - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月11日內容資訊: 英文 287 Pages
簡介

本報告提供骨關節炎(OA)市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 骨關節炎的概要與流行病學研究

第4章 骨關節炎的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 骨關節炎的交易趨勢

第7章 骨關節炎開發平台藥物的專利比較分析

第8章 風險調整淨現值(r-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH225

GervanoRA's pipeline analysis and opportunity assessment report "Osteoarthritis (OA) - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Osteoarthritis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Osteoarthritis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Osteoarthritis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Osteoarthritis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Osteoarthritis historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Osteoarthritis Market (2020) and the Forecasted Osteoarthritis Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Osteoarthritis Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Osteoarthritis Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Osteoarthritis Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: OSTEOARTHRITIS DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: OSTEOARTHRITIS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF OSTEOARTHRITIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF OSTEOARTHRITIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: OA REPORT DATA IN NUMERICALS
  • TABLE 02: OA GLOBAL EPIDEMIOLOGY (2020) AND FORECAST (2021-2030)
  • TABLE 03: OA US EPIDEMIOLOGY (2020) AND FORECAST (2021-2030)
  • TABLE 04: OA GLOBAL CURRENT MARKET (2020) AND FORECAST (2021-2030)
  • TABLE 05: OA US EPIDEMIOLOGY (2020) AND FORECAST (2021-2030)
  • TABLE 06: TOP 11 OSTEOARTHRITIS DEALS RANKED BY TOTAL DEAL VALUE ($ M)
  • TABLE 07: TOTAL DEALS IN CHRONOLOGICAL ORDER (2020-2004)
  • TABLE 08: FDA APPROVED DRUGS FOR OSTEOARTHITIS (2000-2020)
  • TABLE 09: FDA APPROVED DRUGS FOR OSTEOARTHRITIS (PATENT ANALYSIS)
  • TABLE 10: PHASE III MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 11: PHASE II MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 12: PHASE I MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 13: PRECLINICAL STAGE MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 14: EARLY R&D STAGE MOLECULES IN THE OSTEOARTHRITIS PIPELINE
  • TABLE 15: OSTEOARTHRITIS INACTIVE AND DISCONTINUED MOLECULES
  • TABLE 16: OSTEOARTHRITIS PIPELINE ANALYSIS BY INJECTABLE ROA
  • TABLE 17: OSTEOARTHRITIS PIPELINE ANALYSIS BY TOPICAL ROA
  • TABLE 18: OSTEOARTHRITIS PIPELINE ANALYSIS BY ORAL ROA
  • TABLE 19: OSTEOARTHRITIS PIPELINE ANALYSIS, ANTI-INFLAMMATORY DRUG CLASS
  • TABLE 20: ESTIMATED APPROVAL TIMELINES OF OSTEOARTHRITIS PIPELINE DRUGS

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY PIPELINE EVENTS, 2020-2030
  • FIGURE 02: OA GLOBAL EPIDEMIOLOGY FORECAST 2021-2030
  • FIGURE 03: US EPIDEMIOLOGY FORECAST 2021-2030
  • FIGURE 04: OSTEOARTHRITIS MERGERS & ACQUISITIONS BY DEAL TYPE (2004 - 2020)
  • FIGURE 05: GEOGRAPHY-WISE BREAKUP, DEAL MAKERS IN OSTEOARTHRITIS (2004 -2020)
  • FIGURE 06: OSTEOARTHITIS PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 07: OSTEOARTHITIS PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 08: HSD COMPARISON, US V/S EU
  • FIGURE 09: OSTEOARTHITIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 10: OSTEOARTHITIS DRUGS PIPELINE, ROA V/S HSD
  • FIGURE 11: PIPELINE ANALYSIS BY INJECTABLES, SPLIT BY TECHNIQUE USED
  • FIGURE 12: INJECTABLES BY HSD SPLIT-UP
  • FIGURE 13: ORALS BY HSD SPLIT-UP
  • FIGURE 14: OSTEOARTHITIS DRUGS PIPELINE BY DIFFERENT DRUG CLASSES
  • FIGURE 15: ANTI-INFLAMMATORY DRUGS SPLIT BY HSD